

## Merck and Siemens deepen strategic partnership to accelerate AI and data-driven drug discovery and development

- **MoU signed to deliver end-to-end digital workflows from drug discovery to manufacturing through combination of technology from the Siemens Xcelerator platform and Merck's Life Sciences portfolio**
- **Joint projects include developing AI-driven tools and digital interfaces that simplify complex scientific processes**

Merck and Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate digital transformation in the life science industry by connecting digital and physical products. The agreement focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery, development, and manufacturing. This agreement marks the first joint use of technology acquired by Siemens as part of the acquisition of Dotmatics that was completed in July 2025.

“Through this collaboration with Siemens, we are opening new possibilities for scientists to move faster from an idea in the lab to a therapy for patients,” said Jean-Charles Wirth, Member of the Executive Board and CEO Life Science, Merck. “By combining our strengths, we aim to change how science advances, unlocking new ways to accelerate scientific progress.”

“We are partnering with Merck to give scientists around the world the instruments to speed up the development of life-saving medication”, said Cedrik Neike, Member of the Managing Board at Siemens AG and CEO of Siemens Digital Industries. “Every few years the cost for developing a new drug is doubling. Data, AI and digitalization are key to break this paradigm. We are connecting every step of drug development

through a digital backbone – so that data flows seamlessly, insights emerge faster, and medication reaches the patients faster.”

The collaboration will focus on digital-first solutions that close workflow gaps in drug discovery and biomanufacturing by integrating Merck’s software-as-a-service (SaaS) products with Siemens’ digital ecosystem. Initial pilot projects include making Merck’s AI tools and digital applications available in Luma, Siemens’ Scientific Intelligence Platform acquired as part of Dotmatics. This will give scientists a single environment that links product ordering with immediate access to the digital tools and insights they need to make faster, data-driven decisions.

Building on these projects, Siemens and Merck will pursue additional joint projects and explore deeper integration over time. These initiatives include co-developing smarter data management tools and intuitive interfaces that make advanced processes easier for scientists to use. The partnership is also evaluating digital marketplaces that would give customers streamlined access to complementary technologies and services.

Together, Merck and Siemens see digital innovation as central to the future of life sciences. This partnership is designed to set a new standard for digital transformation, giving scientists and manufacturers the tools to deliver breakthroughs faster. It also builds on earlier MoUs between the two companies in smart manufacturing, reflecting a shared commitment to advancing innovation across the industry.

This press release and a press photo are available at: <https://sie.ag/v2kMe>

### **Contact for journalists**

Florian Martini

Phone: +49 174 155 2072; e-mail: [florian.martini@siemens.com](mailto:florian.martini@siemens.com)

**Siemens AG** (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a

majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at [www.siemens.com](https://www.siemens.com)